Results 221 to 230 of about 101,700 (245)

Imatinib and beyond—exploring the full potential of targeted therapy for CML

Nature Reviews Clinical Oncology, 2009
Hagop M Kantarjian
exaly  

Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia

Nature Reviews Cancer, 2007
Andreas Hochhaus
exaly  

Immunological off-target effects of imatinib

Nature Reviews Clinical Oncology, 2016
Laurence Zitvogel, Maha Ayyoub, Guido Kroemer   +2 more
exaly  

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

Lancet, The, 2004
Jaap Verweij, Paolo Giovanni Casali, John Zalcberg   +2 more
exaly  

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial

Lancet, The, 2009
Ronald P Dematteo, Karla V Ballman, Robert G Maki   +2 more
exaly  

Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias

New England Journal of Medicine, 2006
Moshe Talpaz, Hagop M Kantarjian, Charles L Sawyers   +2 more
exaly  

Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

New England Journal of Medicine, 2010
Giuseppe Saglio, Dong-Wook Kim, Surapol Issaragrisil   +2 more
exaly  

Imatinib

Reactions Weekly, 2017
openaire   +2 more sources

Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study

Lancet, The, 2001
Jaap Verweij, Sigrid Stroobants, Raf M Sciot   +2 more
exaly  

Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors

New England Journal of Medicine, 2002
George D Demetri, Margaret von Mehren, David A Tuveson   +2 more
exaly